The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice
Open accessAbstract
Since the 2019 National Lipid Association (NLA) Scientific Statement on Use of Lipoprotein(a) in Clinical Practice was issued, accumulating epidemiological data have clarified the relationship between lipoprotein(a) [Lp(a)] level and cardiovascular disease risk and risk reduction. Therefore, the NLA developed this focused update to guide clinicians in applying this emerging evidence in clinical practice. We now have sufficient evidence to support the recommendation to measure Lp(a) levels at least once in every adult for risk stratification. Individuals with Lp(a) levels <75 nmol/L (30 mg/dL) are considered low risk, individuals with Lp(a) levels ≥125 nmol/L (50 mg/dL) are considered high risk, and individuals with Lp(a) levels between 75 and 125 nmol/L (30-50 mg/dL) are at intermediate risk. Cascade screening of first-degree relatives of patients with elevated Lp(a) can identify additional individuals at risk who require intervention. Patients with elevated Lp(a) should receive early, more-intensive risk factor management, including lifestyle modification and lipid-lowering drug therapy in high-risk individuals, primarily to reduce low-density lipoprotein cholesterol (LDL-C) levels. The U.S. Food and Drug Administration approved an indication for lipoprotein apheresis (which reduces both Lp(a) and LDL-C) in high-risk patients with familial hypercholesterolemia and documented coronary or peripheral artery disease whose Lp(a) level remains ≥60 mg/dL [∼150 nmol/L)] and LDL-C ≥ 100 mg/dL on maximally tolerated lipid-lowering therapy. Although Lp(a) is an established independent causal risk factor for cardiovascular disease, and despite the high prevalence of Lp(a) elevation (∼1 of 5 individuals), measurement rates are low, warranting improved screening strategies for cardiovascular disease prevention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824
Clofibrate and Niacin in Coronary Heart Disease
(1975) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1975.03240160024021 · Cited by 1,747
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Kronenberg, F., Mora, S., Stroes, E. S. G., Ference, B. A., Arsenault, B. J., Berglund, L., Dweck, M. R., Koschinsky, M., Lambert, G., Mach, F., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac361 · Cited by 1,449
Self-citation2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.009 · Cited by 1,193 · cited 2×
“45”
BackgroundSelf-citationLipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial
O’Donoghue, M. L., Fazio, S., Giugliano, R. P., Stroes, E. S. G., Kanevsky, E., Gouni-Berthold, I., Im, K., Lira Pineda, A., Wasserman, S. M., Češka, R., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037184 · Cited by 984 · cited 2×
“PCSK9 inhibitors, including monoclonal antibodies (evolocumab and alirocumab) and small interfering RNAs (siRNAs; inclisiran), can lower Lp(a) by approximately 20– 30 %, 19 , 61 , 62 although they are not approved for this indication.”
BackgroundInfluentialPearson, G. J., Thanassoulis, G., Anderson, T. J., Barry, A. R., Couture, P., Dayan, N., Francis, G. A., Genest, J., Grégoire, J., Grover, S. A., et al. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.03.016 · Cited by 843
Reyes-Soffer, G., Ginsberg, H. N., Berglund, L., Duell, P. B., Heffron, S. P., Kamstrup, P. R., Lloyd-Jones, D. M., Marcovina, S. M., Yeang, C., Koschinsky, M. L., et al. (2022) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000147 · Cited by 836
Self-citationKhan, S. S., Coresh, J., Pencina, M. J., Ndumele, C. E., Rangaswami, J., Chow, S. L., Palaniappan, L. P., Sperling, L. S., Virani, S. S., Ho, J. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001191 · Cited by 797
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease
O’Donoghue, M. L., Rosenson, R. S., Gencer, B., López, J. A. G., Lepor, N. E., Baum, S. J., Stout, E., Gaudet, D., Knusel, B., Kuder, J. F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2211023 · Cited by 599
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
Bittner, V. A., Szarek, M., Aylward, P. E., Bhatt, D. L., Diaz, R., Edelberg, J. M., Fras, Z., Goodman, S. G., Halvorsen, S., Hanotin, C., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.10.057 · Cited by 572
Patel, A. P., Wang, M., Pirruccello, J. P., Ellinor, P. T., Ng, K., Kathiresan, S., & Khera, A. V. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.315291 · Cited by 567
Willeit, P., Ridker, P. M., Nestel, P. J., Simes, J., Tonkin, A. M., Pedersen, T. R., Schwartz, G. G., Olsson, A. G., Colhoun, H. M., Kronenberg, F., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31652-0 · Cited by 564
Khera, A. V., Everett, B. M., Caulfield, M. P., Hantash, F. M., Wohlgemuth, J., Ridker, P. M., & Mora, S. (2014) · Circulation · doi:10.1161/circulationaha.113.004406 · Cited by 461 · cited 1×
“18 The Lp(a)-raising effects of statins are minimal on average, with an approximate 1.1-mg/dL increase or 0.1 % relative increase in Lp(a) on statin treatment as seen in a large meta-analysis.”
MethodInfluentialKenet, G., Lütkhoff, L. K., Albisetti, M., Bernard, T., Bonduel, M., Brandao, L., Chabrier, S., Chan, A., deVeber, G., Fiedler, B., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.913673 · Cited by 449
Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups
Paré, G., Çaku, A., McQueen, M., Anand, S. S., Enas, E., Clarke, R., Boffa, M. B., Koschinsky, M., Wang, X., Yusuf, S., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.034311 · Cited by 382
Self-citationNowak-Göttl, U., Sträter, R., Heinecke, A., Junker, R., Koch, H.-G., Schuierer, G., & von Eckardstein, A. (1999) · Blood · doi:10.1182/blood.v94.11.3678 · Cited by 344
Lipoprotein (a) measurements for clinical application
Marcovina, S. M., & Albers, J. J. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r061648 · Cited by 338 · cited 1×
“37 Therefore, antibodies that recognize epitopes in the KIV2 sequence tend to underestimate the concentrations of smaller Lp(a) isoform sizes (which tend to be associated with higher Lp(a) levels and higher ASCVD risk), while overestimating those of larger isoforms.”
BackgroundVirani, S. S., Brautbar, A., Davis, B. C., Nambi, V., Hoogeveen, R. C., Sharrett, A. R., Coresh, J., Mosley, T. H., Morrisett, J. D., Catellier, D. J., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.045120 · Cited by 324
Self-citationNissen, S. E., Wolski, K., Balog, C., Swerdlow, D. I., Scrimgeour, A. C., Rambaran, C., Wilson, R. J., Boyce, M., Ray, K. K., Cho, L., et al. (2022) · JAMA · doi:10.1001/jama.2022.5050 · Cited by 303
Nissen, S. E., Linnebjerg, H., Shen, X., Wolski, K., Ma, X., Lim, S., Michael, L. F., Ruotolo, G., Gribble, G., Navar, A. M., et al. (2023) · JAMA · doi:10.1001/jama.2023.21835 · Cited by 230
Wright, R. S., Ray, K. K., Raal, F. J., Kallend, D. G., Jaros, M., Koenig, W., Leiter, L. A., Landmesser, U., Schwartz, G. G., Friedman, A., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.12.058 · Cited by 229
Chasman, D. I., Shiffman, D., Zee, R. Y. L., Louie, J. Z., Luke, M. M., Rowland, C. M., Catanese, J. J., Buring, J. E., Devlin, J. J., & Ridker, P. M. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.07.019 · Cited by 228
Varvel, S., McConnell, J. P., & Tsimikas, S. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.308011 · Cited by 218
Guan, W., Cao, J., Steffen, B. T., Post, W. S., Stein, J. H., Tattersall, M. C., Kaufman, J. D., McConnell, J. P., Hoefner, D. M., Warnick, R., et al. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.304785 · Cited by 215
Nicholls, S. J., Nissen, S. E., Fleming, C., Urva, S., Suico, J., Berg, P. H., Linnebjerg, H., Ruotolo, G., Turner, P. K., & Michael, L. F. (2023) · JAMA · doi:10.1001/jama.2023.16503 · Cited by 206
Non-genetic influences on lipoprotein(a) concentrations
Enkhmaa, B., & Berglund, L. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.006 · Cited by 193
Mehta, A., Vasquez, N., Ayers, C. R., Patel, J., Hooda, A., Khera, A., Blumenthal, R. S., Shapiro, M. D., Rodriguez, C. J., Tsai, M. Y., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.11.058 · Cited by 182
Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis
de Boer, L. M., Oorthuys, A. O. J., Wiegman, A., Langendam, M. W., Kroon, J., Spijker, R., Zwinderman, A. H., & Hutten, B. A. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab171 · Cited by 179
Protein-coding repeat polymorphisms strongly shape diverse human phenotypes
Mukamel, R. E., Handsaker, R. E., Sherman, M. A., Barton, A. R., Zheng, Y., McCarroll, S. A., & Loh, P.-R. (2021) · Science · doi:10.1126/science.abg8289 · Cited by 178
Risk factors profile of young and older patients with myocardial infarction
Sagris, M., Antonopoulos, A. S., Theofilis, P., Oikonomou, E., Siasos, G., Tsalamandris, S., Antoniades, C., Brilakis, E. S., Kaski, J. C., & Tousoulis, D. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvab264 · Cited by 171
Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes
Lacaze, P. A., Bakshi, A., Riaz, M., Polekhina, G., Owen, A. J., Bhatia, H. S., Natarajan, P., Wolfe, R. S., Beilin, L. J., Nicholls, S. J., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.07.027 · Cited by 171
Emerging RNA Therapeutics to Lower Blood Levels of Lp(a)
Tsimikas, S., Moriarty, P. M., & Stroes, E. S. G. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.01.051 · Cited by 161
Sahebkar, A., Reiner, Ž., Simental‐Mendía, L. E., Ferretti, G., & Cicero, A. F. G. (2016) · Metabolism · doi:10.1016/j.metabol.2016.08.007 · Cited by 157
Awad, K., Mikhailidis, D. P., Katsiki, N., Muntner, P., & Banach, M. (2018) · Drugs · doi:10.1007/s40265-018-0870-1 · Cited by 139
Lipoprotein(a) Testing Trends in a Large Academic Health System in the United States
Bhatia, H. S., Hurst, S., Desai, P., Zhu, W., & Yeang, C. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.031255 · Cited by 134
Lipoprotein(a) and ethnicities
Mehta, A., Jain, V., Saeed, A., Saseen, J. J., Gulati, M., Ballantyne, C. M., & Virani, S. S. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.005 · Cited by 132
Self-citationLipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic Pooled Prospective Cohort
Wong, N. D., Fan, W., Hu, X., Ballantyne, C. M., Hoogeveen, R. C., Tsai, M. Y., Browne, A., & Budoff, M. J. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.02.031 · Cited by 125
Self-citationPerrot, N., Verbeek, R., Sandhu, M. S., Boekholdt, S. M., Hovingh, G. K., Wareham, N. J., Khaw, K., & Arsenault, B. J. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.11.010 · Cited by 124
Yeang, C., Witztum, J. L., & Tsimikas, S. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100053 · Cited by 124
Repeat Measures of Lipoprotein(a) Molar Concentration and Cardiovascular Risk
Trinder, M., Paruchuri, K., Haidermota, S., Bernardo, R. C., Zekavat, S. M., Gilliland, T., Januzzi, J. L., & Natarajan, P. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.11.055 · Cited by 120
Effect of inclisiran on lipids in primary prevention: the ORION-11 trial
Ray, K. K., Kallend, D., Leiter, L. A., Raal, F. J., Koenig, W., Jaros, M. J., Schwartz, G. G., Landmesser, U., Garcia Conde, L., Wright, R. S., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac615 · Cited by 116 · cited 1×
“PCSK9 inhibitors, including monoclonal antibodies (evolocumab and alirocumab) and small interfering RNAs (siRNAs; inclisiran), can lower Lp(a) by approximately 20– 30 %, 19 , 61 , 62 although they are not approved for this indication.”
BackgroundClinical Trial Design for Lipoprotein(a)-Lowering Therapies
Malick, W. A., Goonewardena, S. N., Köenig, W., & Rosenson, R. S. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.033 · Cited by 116
Larsson, S. C., Gill, D., Mason, A. M., Jiang, T., Bäck, M., Butterworth, A. S., & Burgess, S. (2020) · Circulation · doi:10.1161/circulationaha.120.045826 · Cited by 114
Thomas, P. E., Vedel‐Krogh, S., Nielsen, S. F., Nordestgaard, B. G., & Kamstrup, P. R. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.10.009 · Cited by 113
Sahebkar, A., Simental‐Mendía, L. E., Pirro, M., Banach, M., Watts, G. F., Sirtori, C. R., Al‐Rasadi, K., & Atkin, S. L. (2018) · Scientific Reports · doi:10.1038/s41598-018-36204-7 · Cited by 112
Welsh, P. I., Welsh, C. E., Celis-Morales, C. A., Brown, R., Ho, F. K. W., Ferguson, L. D., Mark, P. B., Lewsey, J., Gray, S. R., Lyall, D. M., et al. (2020) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa063 · Cited by 110
de Boer, L. M., Hof, M. H. P., Wiegman, A., Stroobants, A. K., Kastelein, J. J. P., & Hutten, B. A. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.03.004 · Cited by 102
Lipoprotein(a) in Youth and Prediction of Major Cardiovascular Outcomes in Adulthood
Raitakari, O. T., Kartiosuo, N., Pahkala, K., Hutri‐Kähönen, N., Bazzano, L., Chen, W., Urbina, E. M., Jacobs, D. R., Sinaiko, A. R., Steinberger, J., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.060667 · Cited by 100
Wilson, D. P., Jacobson, T. A., Jones, P. H., Koschinsky, M. L., McNeal, C. J., Nordestgaard, B. G., & Orringer, C. E. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.08.007 · Cited by 97
Self-citationThomas, P. E., Vedel‐Krogh, S., Kamstrup, P. R., & Nordestgaard, B. G. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad055 · Cited by 85
Wilkinson, M. J., Lepor, N. E., & Michos, E. D. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.028892 · Cited by 77
Self-citationRidker, P. M., Lei, L., Ray, K. K., Ballantyne, C. M., Bradwin, G., & Rifai, N. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.02.002 · Cited by 75
Self-citationTargeted Treatment against Lipoprotein (a): The Coming Breakthrough in Lipid Lowering Therapy
Sosnowska, B., Surma, S., & Banach, M. (2022) · Pharmaceuticals · doi:10.3390/ph15121573 · Cited by 70
Review of Lipid and Lipoprotein(a) Abnormalities in Childhood Arterial Ischemic Stroke
Sultan, S. M., Schupf, N., Dowling, M. M., deVeber, G., Kirton, A., & Elkind, M. S. V. (2013) · International Journal of Stroke · doi:10.1111/ijs.12136 · Cited by 67
Szarek, M. J., Reijnders, E., Jukema, J. W., Bhatt, D. L., Bittner, V., Díaz, R., Fazio, S., Garon, G., Goodman, S. G., Harrington, R. A., et al. (2023) · Circulation · doi:10.1161/circulationaha.123.066398 · Cited by 64
Swerdlow, D. I., Rider, D. A., Yavari, A., Lindholm, M., Campion, G., & Nissen, S. E. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab100 · Cited by 62
Arsenault, B. J., Pelletier, W., Kaiser, Y., Perrot, N., Couture, C., Khaw, K., Wareham, N. J., Bossé, Y., Pîbarot, P., Stroes, E. S. G., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.0129 · Cited by 61
Perrot, N., Thériault, S., Dina, C., Chen, H. Y., Boekholdt, S. M., Rigade, S., Després, A.-A., Poulin, A., Capoulade, R., Tourneau, T. L., et al. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.1581 · Cited by 60
Stürzebecher, P. E., Schorr, J., Klebs, S. H. G., & Laufs, U. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.01.014 · Cited by 59
Lipoprotein(a) Levels at Birth and in Early Childhood: The COMPARE Study
Strandkjær, N., Hansen, M. K., Nielsen, S. T., Frikke‐Schmidt, R., Tybjærg‐Hansen, A., Nordestgaard, B. G., Tabor, A., Bundgaard, H., Iversen, K. K., & Kamstrup, P. R. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab734 · Cited by 56
Contemporary patterns of lipoprotein(a) testing and associated clinical care and outcomes
Kelsey, M. D., Mulder, H. S., Chiswell, K., Lampron, Z. M., Nilles, E. K., Kulinski, J. P., Joshi, P. H., Jones, W. S., Chamberlain, A. M., Leucker, T. M., et al. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100478 · Cited by 49
Safarova, M. S., & Moriarty, P. M. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01113-2 · Cited by 44
Self-citationMichos, E. D., Blaha, M. J., & Blumenthal, R. S. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.10.001 · Cited by 43
Self-citationTemporal Trends in Lipoprotein(a) Concentrations: The Atherosclerosis Risk in Communities Study
Deshotels, M. R., Sun, C., Nambi, V., Virani, S. S., Matsushita, K., Yu, B., Ballantyne, C. M., & Hoogeveen, R. C. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.026762 · Cited by 36
Self-citationCao, Y., Zhang, H., Jin, J., Liu, H., Zhang, Y., Zhang, M., Gao, Y., Guo, Y., Wu, N., Zhu, C., et al. (2020) · Thrombosis and Haemostasis · doi:10.1055/a-1340-2109 · Cited by 32
Lipoprotein(a) and Coronary Artery Disease Risk Without a Family History of Heart Disease
Finneran, P., Pampana, A., Khetarpal, S. A., Trinder, M., Patel, A. P., Paruchuri, K., Aragam, K. G., Peloso, G. M., & Natarajan, P. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.017470 · Cited by 31
Jackson, C. L., Garg, P. K., Guan, W., Tsai, M. Y., Criqui, M. H., Tsimikas, S., & Bhatia, H. S. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.06.002 · Cited by 30
Quantification of LDL-Cholesterol Corrected for Molar Concentration of Lipoprotein(a)
Rosenson, R. S., López, J. A. G., Monsalvo, M. L., Wu, Y., Wang, H., & Marcovina, S. M. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07407-y · Cited by 29
Trends in testing and prevalence of elevated Lp(a) among patients with aortic valve stenosis
Bhatia, H. S., Ma, G. S., Taleb, A., Wilkinson, M. J., Kahn, A. M., Cotter, B. R., Yeang, C., DeMaria, A. N., Patel, M. P., Mahmud, E., et al. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.01.022 · Cited by 26
Self-citationWilkinson, M. J., Ma, G. S., Yeang, C., Ang, L., Strachan, M., DeMaria, A. N., Tsimikas, S., & Cotter, B. R. (2017) · Angiology · doi:10.1177/0003319716688415 · Cited by 23
Self-citationGenetic Predictor to Identify Individuals With High Lipoprotein(a) Concentrations
Dron, J. S., Wang, M., Patel, A. P., Kartoun, U., Ng, K., Hegele, R. A., & Khera, A. V. (2021) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.120.003182 · Cited by 19
Marcovina, S. M., & Shapiro, M. D. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.11.053 · Cited by 18
The Value of Measuring Lipoprotein(a) in Children
Khoury, M., & Clarke, S. L. (2022) · Circulation · doi:10.1161/circulationaha.122.062592 · Cited by 16
Lipoprotein(a) in Patients Undergoing Transcatheter Aortic Valve Replacement
Ma, G. S., Wilkinson, M. J., Reeves, R. R., Yeang, C., DeMaria, A. N., Cotter, B. R., Patel, M. P., Mahmud, E., & Tsimikas, S. (2019) · Angiology · doi:10.1177/0003319719826461 · Cited by 15
Self-citationZheng, W., Chilazi, M. J., Park, J., Sathiyakumar, V., Donato, L. J., Meeusen, J. W., Lazo, M., Guallar, E., Kulkarni, K. R., Jaffe, A. S., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023136 · Cited by 15
Sukkari, M. H., Al-bast, B., Tamimi, R. A., Giesing, W., & Siddique, M. S. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100579 · Cited by 15
Case report of male child with elevated lipoprotein (a) leading to acute ischemic stroke
Moriarty, P. M., Tennant, H. M., Sehar, N., Denney, L., Luna, P., Marquès, F. P., Panchal, A. K., Abraham, M. G., & Leever, J. D. (2017) · Journal of Clinical Apheresis · doi:10.1002/jca.21525 · Cited by 12
Lipoprotein(a) lowering and cardiovascular risk reduction by PCSK9 inhibitors
Safarova, M. S., & Kullo, I. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.10.010 · Cited by 5
Self-citation
Cited by
Martin, S. S., Aday, A. W., Allen, N. B., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Bansal, N., Beaton, A. Z., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001303 · Cited by 1,080
Self-citationLipoprotein(a) and cardiovascular disease
Nordestgaard, B. G., & Langsted, A. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01308-4 · Cited by 288
Soffer, D. E., Marston, N. A., Maki, K. C., Jacobson, T. A., Bittner, V. A., Peña, J. M., Thanassoulis, G., Martin, S. S., Kirkpatrick, C. F., Virani, S. S., et al. (2024) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2024.08.013 · Cited by 115
Self-citation
Metadata
- Authors
- Koschinsky, M. L., Bajaj, A., Boffa, M. B., Dixon, D. L., Ferdinand, K. C., Gidding, S. S., Gill, E. A., Jacobson, T. A., Michos, E. D., Safarova, M. S., Soffer, D. E., Taub, P. R., Wilkinson, M. J., Wilson, D. P., & Ballantyne, C. M.
- Venue
- Journal of Clinical Lipidology
- Publisher
- Elsevier BV
- Published
- 2024-05
- Volume
- 18
- Issue
- 3
- Pages
- e308-e319
- ISSN
- 1876-4789 (ISSN-L)
- 1933-2874
- OpenAlex
- W4393386912
- Cited by
- 328
- References
- 81
- FWCI
- 125.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.